Medicinal Bioconvergence Research Center

Yonsei University

Korea Research Institute of Chemical Technology

Snu Rdb Foundation

Gachon University of Industry-academic Cooperation Foundation

Gil Medical Center

Enerceramic Inc.

Jung Min Han

Sunghoon Kim

Jong Hyun Kim

Yang Kook Sun

Chulho Lee

Kyung Eun Park

Dong Ju Jeon

Jong Hwan Song

Cheol Soo Choi

Gyoonhee Han

Mee Sup Yoon

Jie Chen

Kook Son

Woo Seong Kim

Hyeong Rae Kim

The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.

Compound as mTOR inhibitor and use thereof

The present invention relates to a composition comprising the UNE-L domain of leucyl-tRNA synthetase as an effective ingredient for increasing muscle. More particularly, the UNE-L domain of LRS according to the present invention, which is a region that controls activity of Vps34, activates mTORC1 involved in protein synthesis and increases myocyte differentiation and muscle fiber regeneration, thus finding useful application in muscle augmentation.

Composition comprising UNE-L domain of leucyl-tRNA synthetase as effective ingredient for augmenting muscle

The present invention relates to novel 2,4-pyrimidine derivatives and a use thereof, and more particularly, to pyrimidine derivatives which are effective for systemic lupus erythematosus, a composition for preventing and treating systemic lupus erythematosus comprising the same as an active ingredient and a method for screening the same. The present inventors found novel materials inhibiting surface translocation of gp96 by mimicking a function of AIMP1 which is a molecular anchor for an intracellular residence of gp96, and identified in vitro and in vivo activity of the materials for preventing and treating SLE by alleviating SLE plasma in autoimmune diseases. Therefore, the present invention provides a novel method for screening a therapeutic agent for SLE, and preventing or treating SLE using the mechanism.

2, 4-pyrimidine derivatives and use thereof

Provided is a method of screening for agents for preventing or treating mTORC 1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells.

Use of leucyl tRNA synthetase

Disclosed herein is a cathode active material coated with a fluorine compound for lithium secondary batteries. The cathode active material is structurally stable, and improves the charge-discharge characteristics, cycle characteristics, high-voltage characteristics, high-rate characteristics and thermal stability of batteries.

Cathode active material coated with flourine compound for lithium secondary batteries and method for preparing the same

Growing community of inventors

Seoul, South Korea

Jung Min Han